{"id":"regular-insulin-added-to-tpn-bag","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Lipodystrophy at injection sites"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"When added to TPN bags, regular insulin acts on insulin receptors to enhance glucose utilization by peripheral tissues and suppress hepatic glucose production. This prevents hyperglycemia that commonly occurs during parenteral nutrition, particularly in critically ill or stressed patients, and supports protein synthesis and metabolic stability.","oneSentence":"Regular insulin lowers blood glucose by facilitating cellular glucose uptake and promoting anabolic metabolism in patients receiving total parenteral nutrition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:04:36.740Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperglycemia management in patients receiving total parenteral nutrition (TPN)"},{"name":"Blood glucose control in critically ill patients on parenteral nutrition support"}]},"trialDetails":[{"nctId":"NCT02706119","phase":"PHASE4","title":"Insulin in Total Parenteral Nutrition","status":"COMPLETED","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2016-07-01","conditions":"Diabetes Mellitus","enrollment":163},{"nctId":"NCT02216799","phase":"PHASE4","title":"Glargine Insulin vs.Continuous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN)","status":"COMPLETED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2013-03","conditions":"Diabetic Patients With Gastrointestinal Cancer Undergoing Surgery and Receiving Parenteral Nutrition","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ATC code A10AB01","Actrapid®"],"phase":"marketed","status":"active","brandName":"Regular insulin added to TPN bag","genericName":"Regular insulin added to TPN bag","companyName":"Fundación Pública Andaluza Progreso y Salud","companyId":"fundaci-n-p-blica-andaluza-progreso-y-salud","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Regular insulin lowers blood glucose by facilitating cellular glucose uptake and promoting anabolic metabolism in patients receiving total parenteral nutrition. Used for Hyperglycemia management in patients receiving total parenteral nutrition (TPN), Blood glucose control in critically ill patients on parenteral nutrition support.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}